Skip to content

Clinical trials

Phase 4 Crohn Disease trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Crohn Disease Phase: Phase 4 Clear all

150 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20031
20041
20056
20072
20087
20095
20106
20115
20127
20138
20147
201511
20169
20178
20185
20196
20203
20218
20228
20237
20247
20257
202613

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed61
Recruiting26
Unknown status23
Terminated19
Withdrawn9
Not yet recruiting8
Enrolling by invitation2
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Takeda10
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives9
Sixth Affiliated Hospital, Sun Yat-sen University5
Alimentiv Inc.4
Asan Medical Center3
Erasmus Medical Center3
Mayo Clinic3
Prof. Arie Levine3
AbbVie2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Crohn Disease150
Colitis, Ulcerative43
Inflammatory Bowel Diseases36
Vitamin D Deficiency4
Arthritis, Psoriatic3
Arthritis, Rheumatoid3
Bone Diseases, Metabolic3
Intestinal Diseases3
Iron Deficiencies3
Digestive System Diseases2

Trials

Showing 26 to 50 of 150. Each trial links to its page on Pharma Observatory.

50 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.